Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | SVP, Chief Operating Officer | March 08, 2023 | March 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date March 08, 2023 · Filed March 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 376,316 |
Reported balance
After 2023-03-08 transaction · row 1
1 source rowRow 1 · 2023-03-08 · Grant · Acquired 43,668 · Balance 376,316 F1: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. |
| Performance-based Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-02-28 | Direct | 21,834 |
Reported balance
After 2023-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-08 · Grant · Acquired 21,834 · Balance 21,834 F2: Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
F2: Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2023 Filed Mar 10, 2023 17:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantPerformance-based Restricted Stock Units · Derivative | 21,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017886 · doc4.xml · derivative · entry 2 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,834 Underlying: Class A Common Stock · 21,834 shares Expires 2026-02-28 F2 · derivative.exercise_price: Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share. F2 · derivative.exercise_date: Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 17:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 43,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017886 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,316 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 18:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,442 | $11.31 | $38,929.02 |
DisclosureSEC source: 0001209191-23-014285 · doc4.xml · nonDerivative · entry 4 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,648 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units granted on February 27, 2020. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 18:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 13,987 | $11.31 | $158,192.97 |
DisclosureSEC source: 0001209191-23-014285 · doc4.xml · nonDerivative · entry 3 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,090 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 18:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,308 | $11.41 | $37,744.28 |
DisclosureSEC source: 0001209191-23-014285 · doc4.xml · nonDerivative · entry 2 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,077 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units granted on February 27, 2020. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 18:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 13,438 | $11.41 | $153,327.58 |
DisclosureSEC source: 0001209191-23-014285 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,385 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 16:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 18,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003991 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,823 F1 · kind: Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted February 27, 2020. The earned PSUs were certified and vested on January 17, 2023. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 16:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 27,000 | $12.39 | $334,530.00 |
DisclosureSEC source: 0001209191-22-061644 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,736 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.38 to $12.41,inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 994 | $11.77 | $11,699.38 |
DisclosureSEC source: 0001209191-22-046223 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,736 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on September 4, 2018. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 16:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 18,041 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0001209191-22-045179 · doc4.xml · derivative · entry 5 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 18,041 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 16:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 18,041 | $11.75 | $211,981.75 |
DisclosureSEC source: 0001209191-22-045179 · doc4.xml · nonDerivative · entry 4 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,730 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.74 to $11.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 16:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 18,041 | $11.65 | $210,177.65 |
DisclosureSEC source: 0001209191-22-045179 · doc4.xml · nonDerivative · entry 3 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 16:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,236 | $11.56 | $25,848.16 |
DisclosureSEC source: 0001209191-22-045179 · doc4.xml · nonDerivative · entry 2 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,730 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 16:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 27,200 | $11.64 | $316,608.00 |
DisclosureSEC source: 0001209191-22-045179 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,966 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.63 to $11.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: The reporting person acquired 2,092 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
| May 23, 2022 Filed May 25, 2022 16:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 12,760 | $11.50 | $146,740.00 |
DisclosureSEC source: 0001209191-22-031841 · doc4.xml · nonDerivative · entry 2 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,074 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 50% of the reporting person's restricted stock units granted on March 26, 2021. Read SEC document |
| May 23, 2022 Filed May 25, 2022 16:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 777 | $11.50 | $8,935.50 |
DisclosureSEC source: 0001209191-22-031841 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,834 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2019. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 16:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 90,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016187 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,611 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 16:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 6,820 | $10.77 | $73,451.40 |
DisclosureSEC source: 0001209191-22-014650 · doc4.xml · nonDerivative · entry 5 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,113 F5 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 16:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 11,057 | $10.77 | $119,083.89 |
DisclosureSEC source: 0001209191-22-014650 · doc4.xml · nonDerivative · entry 4 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,933 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 16:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 6,022 | $10.77 | $64,856.94 |
DisclosureSEC source: 0001209191-22-014650 · doc4.xml · nonDerivative · entry 3 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,990 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 16:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,150 | $10.77 | $33,925.50 |
DisclosureSEC source: 0001209191-22-014650 · doc4.xml · nonDerivative · entry 2 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,012 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 16:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,913 | $10.77 | $20,603.01 |
DisclosureSEC source: 0001209191-22-014650 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,162 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 17:55 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 36,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-006549 · tm224209-2_4seq1.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,075 F1 · kind: Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted February 27, 2020. The earned PSUs were certified and vested on January 19, 2022. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 27,000 | $11.28 | $304,560.00 |
DisclosureSEC source: 0001209191-21-070549 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,901 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.28 to $11.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: The reporting person acquired 2,236 shares of Class A common stock under the issuer's employee stock purchase plan on June 30, 2021. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 16:09 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 16,766 | $11.58 | $194,150.28 |
DisclosureSEC source: 0001209191-21-066782 · doc4.xml · nonDerivative · entry 2 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,665 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 100% of the reporting person's restricted stock units granted on December 16, 2019. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 16:09 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 427 | $11.58 | $4,944.66 |
DisclosureSEC source: 0001209191-21-066782 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,431 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 680 | $13.48 | $9,166.40 |
DisclosureSEC source: 0001209191-21-052199 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,858 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on September 4, 2018. Read SEC document |
| May 24, 2021 Filed May 26, 2021 16:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 516 | $12.25 | $6,321.00 |
DisclosureSEC source: 0001209191-21-035900 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,538 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2019. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 17:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 56,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023574 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,054 F1 · kind: The restricted stock units, granted as a retention award, vest as to 50% of the shares of Class A Common Stock on each of May 19, 2022 and May 18, 2023. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:43 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 6,159 | $9.11 | $56,108.49 |
DisclosureSEC source: 0001209191-21-016099 · doc4.xml · nonDerivative · entry 4 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,682 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:43 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,197 | $9.11 | $29,124.67 |
DisclosureSEC source: 0001209191-21-016099 · doc4.xml · nonDerivative · entry 3 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,841 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:43 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,627 | $9.11 | $14,821.97 |
DisclosureSEC source: 0001209191-21-016099 · doc4.xml · nonDerivative · entry 2 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,038 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:43 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,668 | $9.11 | $24,305.48 |
DisclosureSEC source: 0001209191-21-016099 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,665 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 84,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013762 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,333 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 394 | $10.92 | $4,302.48 |
DisclosureSEC source: 0001209191-20-057617 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,382 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 15, 2017. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 16:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 689 | $10.14 | $6,986.46 |
DisclosureSEC source: 0001209191-20-047472 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,776 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on September 4, 2018. F2 · balance_after: The reporting person acquired 1,885 shares of Class A common stock under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| May 11, 2020 Filed May 13, 2020 17:23 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 510 | $10.35 | $5,278.50 |
DisclosureSEC source: 0001209191-20-028906 · doc4.xml · nonDerivative · entry 1 Rickard Jason · CIK 0001808505 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,580 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.